Gastroparesis Drugs Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion

Market Dynamics of Gastroparesis Drugs Market Analysis

Growth Drivers

  • An increasing prevalence of gastroparesis disorder propels the growth of the gastroparesis drugs market.
  • An increasing incidence of diabetes boosts the market for gastroparesis drugs.  

Restraints

  • Serious side effects of gastroparesis drugs restrain the market growth.   

Trends

  • Research and development efforts to treat gastroparesis may represent a significant opportunity to drive the market.   

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

Gastroparesis Drugs Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Regional and Country Analysis

Global Gastroparesis Drugs Market Analysis 2026

Region / Country 2021 (A)2025 (A)2033 (P) CAGR
Globalxxxxxxxxxxxxxxxx
North Americaxxxxxxxxxxxxxxxx
United Statesxxxxxxxxxxxxxxxx
Canadaxxxxxxxxxxxxxxxx
Mexicoxxxxxxxxxxxxxxxx
Europexxxxxxxxxxxxxxxx
United Kingdomxxxxxxxxxxxxxxxx
Francexxxxxxxxxxxxxxxx
Germanyxxxxxxxxxxxxxxxx
Italyxxxxxxxxxxxxxxxx
Russiaxxxxxxxxxxxxxxxx
Spainxxxxxxxxxxxxxxxx
Swedenxxxxxxxxxxxxxxxx
Denmarkxxxxxxxxxxxxxxxx
Switzerlandxxxxxxxxxxxxxxxx
Luxembourgxxxxxxxxxxxxxxxx
Rest of Europexxxxxxxxxxxxxxxx
Asia Pacificxxxxxxxxxxxxxxxx
Chinaxxxxxxxxxxxxxxxx
Japanxxxxxxxxxxxxxxxx
South Koreaxxxxxxxxxxxxxxxx
Indiaxxxxxxxxxxxxxxxx
Australiaxxxxxxxxxxxxxxxx
Singaporexxxxxxxxxxxxxxxx
Taiwanxxxxxxxxxxxxxxxx
South East Asiaxxxxxxxxxxxxxxxx
Rest of APACxxxxxxxxxxxxxxxx
South Americaxxxxxxxxxxxxxxxx
Brazilxxxxxxxxxxxxxxxx
Argentinaxxxxxxxxxxxxxxxx
Colombiaxxxxxxxxxxxxxxxx
Peruxxxxxxxxxxxxxxxx
Chilexxxxxxxxxxxxxxxx
Rest of South Americaxxxxxxxxxxxxxxxx
Middle Eastxxxxxxxxxxxxxxxx
Saudi Arabiaxxxxxxxxxxxxxxxx
Turkeyxxxxxxxxxxxxxxxx
UAExxxxxxxxxxxxxxxx
Egyptxxxxxxxxxxxxxxxx
Qatarxxxxxxxxxxxxxxxx
Rest of Middle Eastxxxxxxxxxxxxxxxx
Africaxxxxxxxxxxxxxxxx
East Africaxxxxxxxxxxxxxxxx
West Africaxxxxxxxxxxxxxxxx
North Africaxxxxxxxxxxxxxxxx
South Africaxxxxxxxxxxxxxxxx

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis

Segment Performance in The Gastroparesis Drugs Market Drug Type Segment Analysis By drug class, the prokinetic agent's segment accounted for the highest share in the global gastroparesis drugs market due to the drug's ability to improve gastrointestinal motility, treat delayed stomach emptying, and relieve patients' symptoms; as a result, both patients and healthcare professionals have adopted these drugs widely. Prokinetic medicines are a class of medications that increase the contraction of the stomach muscles, hence improving the stomach's general mobility. Patients with gastroparesis, which impairs digestion and induces symptoms like nausea and vomiting, are often administered them. Because prokinetic medicines can address the underlying cause of the ailment, they are regarded as a cornerstone in the treatment of gastroparesis. These medications have not only been used to treat gastroparesis but have also been investigated for their safety and efficacy in critically ill patients undergoing enteral nutrition, with encouraging findings in lowering feeding intolerance in these patients. For instance, in December 2023, The US Food and Drug Administration (FDA) accepted the new drug application (NDA) filed by Vanda Pharmaceuticals for its drug tradipitant to treat gastroparesis. Source:(https://www.pharmaceutical-technology.com/news/fda-vanda-gastroparesis-treatment/)

Antiemetic Agents Gastroparesis Drugs Market Analysis
XX
Antiemetic Agents Market Size 2025
XX %
CAGR
Locked · Full data in paid report
Prokinetic Agents Gastroparesis Drugs Market Analysis
XX
Prokinetic Agents Market Size 2025
XX %
CAGR
Locked · Full data in paid report
Botulinum Toxin Injections Gastroparesis Drugs Market Analysis
XX
Botulinum Toxin Injections Market Size 2025
XX %
CAGR
Locked · Full data in paid report

Market size by (Illustrative, 2025)
Share distribution (2025)

Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.

To learn more about market share and segmentation, request the free sample pages.

Competitor Analysis

Competitive Landscape: The Gastroparesis Drugs Market

Companies are implementing strategies such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to sustain in the market. Pharmaceutical firms are always working to enhance their medications' effectiveness, safety, motility, and affordability for the treatment of gastroparesis. Additionally, Companies want approval of their product by government organizations like the US FDA and the European Medicines Agency.
For instance, in March 2024 – Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company focused on developing groundbreaking medications for patients suffering from gastrointestinal (GI) disorders, and its European partner, Dr. Falk Pharma GmbH (Dr. Falk Pharma), is pleased to announce that FDA has granted clearance for the Investigational New Drug (IND) application for naronapride, a treatment for patients with gastroparesis.
Source:(https://www.biospace.com/article/releases/renexxion-ireland-ltd-and-dr-falk-pharma-gmbh-announce-fda-clearance-of-the-investigational-new-drug-application-for-naronapride-to-treat-gastroparesis-and-subsequent-expansion-of-the-ongoing-phase-2b-move-it-study-to-the-united-states/)

Click any bar or cell to request the full company profile
Top Companies (In no particular order)2022 (A)2023 (A)2024 (A)2025 (A)
Medtronic••• ••• ••• •••
Kimberly-Clark Corporation••• ••• ••• •••
Abbott Laboratories••• ••• ••• •••
Salix Pharmaceuticals••• ••• ••• •••
Inc••• ••• ••• •••
Boston Scientific Corporation••• ••• ••• •••
C. R. Bard••• ••• ••• •••
Inc••• ••• ••• •••
Janssen Global Services LLC••• ••• ••• •••
Cardinal Health••• ••• ••• •••
Inc.••• ••• ••• •••
Alfa Wassermann SPA••• ••• ••• •••
Evoke Pharma••• ••• ••• •••
Rhythm Pharmaceuticals••• ••• ••• •••
Inc.••• ••• ••• •••
Kimberly-Clark Corporation••• ••• ••• •••
Abbott Laboratories••• ••• ••• •••
Salix Pharmaceuticals••• ••• ••• •••
Inc••• ••• ••• •••
Boston Scientific Corporation••• ••• ••• •••
C. R. Bard••• ••• ••• •••
Inc••• ••• ••• •••
Janssen Global Services LLC••• ••• ••• •••
Cardinal Health••• ••• ••• •••
Inc.••• ••• ••• •••
Alfa Wassermann SPA••• ••• ••• •••
Evoke Pharma••• ••• ••• •••
Rhythm Pharmaceuticals••• ••• ••• •••
Inc••• ••• ••• •••

We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.

Request company profile for validation →

Report Scope & Analysis

According to Cognitive Market Research, The Gastroparesis Drugs Market was USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031. 
North America held the major market share for more than XX% of the global revenue with a market size of USD XX  million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031.
The  Europe region is the fastest growing market with a CAGR of XX% from 2024 to 2031 and it is projected that it will grow at a CAGR of XX% in the future.
Asia Pacific  accounted for a market share of over XX% of the global revenue with a market size of USD XX million.
Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
The Gastroparesis Drugs Market held the highest market revenue share in 2024.
 

Introduction of The Gastroparesis Drugs Market

Gastroparesis means paralysis of the stomach. It’s a functional disorder affecting your stomach nerves and muscles. It makes your stomach muscle contractions weaker and slower than they need to be to digest your food and pass it on to your intestines. This leads to food sitting too long in your stomach. Symptoms include nausea, vomiting, abdominal pain, feeling full soon after beginning to eat (early satiety), abdominal bloating, and heartburn. Medications to treat gastroparesis may include metoclopramide (Reglan) and erythromycin. Medications to control nausea and vomiting include diphenhydramine (Benadryl, others) and ondansetron (Zofran). Prochlorperazine (Compro).
The market is expected to grow due to several factors, including rising healthcare costs, growing government support for gastroparesis management, growing awareness of gastroparesis and available treatment options, rising numbers of R&D activities for novel gastroparesis drugs, and advancements in diagnostic technologies. The global market for gastroparesis drugs is expected to grow at a faster rate due to the introduction of novel drug delivery systems, the development of better healthcare facilities and infrastructure, and the rising demand for safe and effective medications to treat the symptoms of gastroparesis.

Analyst Conclusion

With the help of the above study about the gastroparesis drugs market, it can be concluded that the market for gastroparesis drugs worldwide is expected to develop significantly shortly. From the report, one can understand and infer the market dynamics, segmentations, status and trends, and key players in the market. It provides data regarding various topics such as market dimensions, prevailing trends, competitive landscape, and the outlook for prospective expansion. This allows the reader to understand and access reliable data about the market and industry.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst
LinkedIn Profile Book a free Consultation

Frequently Asked Questions

Gastroparesis Drugs Market Analysis market size and growth rate is provided in the report covering 2021-2025 historical and 2025-2033 forecast data.
Major factors including drivers, restraints, opportunities and challenges are analyzed with detailed insights.
Top manufacturers Medtronic, Kimberly-Clark Corporation, Abbott Laboratories, Salix Pharmaceuticals, Inc, Boston Scientific Corporation, C. R. Bard, Inc, Janssen Global Services LLC, Cardinal Health, Inc., Alfa Wassermann SPA, Evoke Pharma, Rhythm Pharmaceuticals, Inc., Kimberly-Clark Corporation, Abbott Laboratories, Salix Pharmaceuticals, Inc, Boston Scientific Corporation, C. R. Bard, Inc, Janssen Global Services LLC, Cardinal Health, Inc., Alfa Wassermann SPA, Evoke Pharma, Rhythm Pharmaceuticals, Inc and others are profiled in the report.
Segments include Drug Type, End-User and additional sub-segments.
Regional analysis covers all major markets. The report identifies the dominant region and provides country-level data.
Sample pages can be obtained on demand from the website. 24/7 chat support and direct call services are available.

★ Reviews

Rate this report

Gastroparesis Drugs Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
Drug TypeAntiemetic Agents, Prokinetic Agents, Botulinum Toxin Injections
End-UserHospitals, Clinics, Pharmacies
Disease Type Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types
List of CompetitorsMedtronic, Kimberly-Clark Corporation, Abbott Laboratories, Salix Pharmaceuticals, Inc, Boston Scientific Corporation, C. R. Bard, Inc, Janssen Global Services LLC, Cardinal Health, Inc., Alfa Wassermann SPA, Evoke Pharma, Rhythm Pharmaceuticals, Inc., Kimberly-Clark Corporation, Abbott Laboratories, Salix Pharmaceuticals, Inc, Boston Scientific Corporation, C. R. Bard, Inc, Janssen Global Services LLC, Cardinal Health, Inc., Alfa Wassermann SPA, Evoke Pharma, Rhythm Pharmaceuticals, Inc

  • Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))

    • 1.1 Top Competitors Analysis
      • 1.1.1 Global Gastroparesis Drugs Market Analysis by Key Players
      • 1.1.2 Segment Market Analysis by Key Players
      • 1.1.3 Top Players Ranking 2024
      • 1.1.4 New Product Launch Analysis
      • 1.1.5 Industry Mergers and Acquisition Analysis
    • 1.2 Company Profile (Data Subject to Availability) Sample Format
      • 1.2.1 Medtronic
        • 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.1.2 Business Overview
        • 1.2.1.3 Financials (Subject to data availability)
        • 1.2.1.4 R&D Investment (Subject to data availability)
        • 1.2.1.5 Product Types Specification
        • 1.2.1.6 Business Strategy
        • 1.2.1.7 Recent Developments
        • 1.2.1.8 Management Change
        • 1.2.1.9 S.W.O.T Analysis
      • 1.2.2 Kimberly-Clark Corporation
        • 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.2.2 Business Overview
        • 1.2.2.3 Financials (Subject to data availability)
        • 1.2.2.4 R&D Investment (Subject to data availability)
        • 1.2.2.5 Product Types Specification
        • 1.2.2.6 Business Strategy
        • 1.2.2.7 Recent Developments
        • 1.2.2.8 Management Change
        • 1.2.2.9 S.W.O.T Analysis
      • 1.2.3 Abbott Laboratories
        • 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.3.2 Business Overview
        • 1.2.3.3 Financials (Subject to data availability)
        • 1.2.3.4 R&D Investment (Subject to data availability)
        • 1.2.3.5 Product Types Specification
        • 1.2.3.6 Business Strategy
        • 1.2.3.7 Recent Developments
        • 1.2.3.8 Management Change
        • 1.2.3.9 S.W.O.T Analysis
      • 1.2.4 Salix Pharmaceuticals
        • 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.4.2 Business Overview
        • 1.2.4.3 Financials (Subject to data availability)
        • 1.2.4.4 R&D Investment (Subject to data availability)
        • 1.2.4.5 Product Types Specification
        • 1.2.4.6 Business Strategy
        • 1.2.4.7 Recent Developments
        • 1.2.4.8 Management Change
        • 1.2.4.9 S.W.O.T Analysis
      • 1.2.5 Inc
        • 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.5.2 Business Overview
        • 1.2.5.3 Financials (Subject to data availability)
        • 1.2.5.4 R&D Investment (Subject to data availability)
        • 1.2.5.5 Product Types Specification
        • 1.2.5.6 Business Strategy
        • 1.2.5.7 Recent Developments
        • 1.2.5.8 Management Change
        • 1.2.5.9 S.W.O.T Analysis
      • 1.2.6 Boston Scientific Corporation
        • 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.6.2 Business Overview
        • 1.2.6.3 Financials (Subject to data availability)
        • 1.2.6.4 R&D Investment (Subject to data availability)
        • 1.2.6.5 Product Types Specification
        • 1.2.6.6 Business Strategy
        • 1.2.6.7 Recent Developments
        • 1.2.6.8 Management Change
        • 1.2.6.9 S.W.O.T Analysis
      • 1.2.7 C. R. Bard
        • 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.7.2 Business Overview
        • 1.2.7.3 Financials (Subject to data availability)
        • 1.2.7.4 R&D Investment (Subject to data availability)
        • 1.2.7.5 Product Types Specification
        • 1.2.7.6 Business Strategy
        • 1.2.7.7 Recent Developments
        • 1.2.7.8 Management Change
        • 1.2.7.9 S.W.O.T Analysis
      • 1.2.8 Inc
        • 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.8.2 Business Overview
        • 1.2.8.3 Financials (Subject to data availability)
        • 1.2.8.4 R&D Investment (Subject to data availability)
        • 1.2.8.5 Product Types Specification
        • 1.2.8.6 Business Strategy
        • 1.2.8.7 Recent Developments
        • 1.2.8.8 Management Change
        • 1.2.8.9 S.W.O.T Analysis
      • 1.2.9 Janssen Global Services LLC
        • 1.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.9.2 Business Overview
        • 1.2.9.3 Financials (Subject to data availability)
        • 1.2.9.4 R&D Investment (Subject to data availability)
        • 1.2.9.5 Product Types Specification
        • 1.2.9.6 Business Strategy
        • 1.2.9.7 Recent Developments
        • 1.2.9.8 Management Change
        • 1.2.9.9 S.W.O.T Analysis
      • 1.2.10 Cardinal Health
        • 1.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.10.2 Business Overview
        • 1.2.10.3 Financials (Subject to data availability)
        • 1.2.10.4 R&D Investment (Subject to data availability)
        • 1.2.10.5 Product Types Specification
        • 1.2.10.6 Business Strategy
        • 1.2.10.7 Recent Developments
        • 1.2.10.8 Management Change
        • 1.2.10.9 S.W.O.T Analysis
      • 1.2.11 Inc.
        • 1.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.11.2 Business Overview
        • 1.2.11.3 Financials (Subject to data availability)
        • 1.2.11.4 R&D Investment (Subject to data availability)
        • 1.2.11.5 Product Types Specification
        • 1.2.11.6 Business Strategy
        • 1.2.11.7 Recent Developments
        • 1.2.11.8 Management Change
        • 1.2.11.9 S.W.O.T Analysis
      • 1.2.12 Alfa Wassermann SPA
        • 1.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.12.2 Business Overview
        • 1.2.12.3 Financials (Subject to data availability)
        • 1.2.12.4 R&D Investment (Subject to data availability)
        • 1.2.12.5 Product Types Specification
        • 1.2.12.6 Business Strategy
        • 1.2.12.7 Recent Developments
        • 1.2.12.8 Management Change
        • 1.2.12.9 S.W.O.T Analysis
      • 1.2.13 Evoke Pharma
        • 1.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.13.2 Business Overview
        • 1.2.13.3 Financials (Subject to data availability)
        • 1.2.13.4 R&D Investment (Subject to data availability)
        • 1.2.13.5 Product Types Specification
        • 1.2.13.6 Business Strategy
        • 1.2.13.7 Recent Developments
        • 1.2.13.8 Management Change
        • 1.2.13.9 S.W.O.T Analysis
      • 1.2.14 Rhythm Pharmaceuticals
        • 1.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.14.2 Business Overview
        • 1.2.14.3 Financials (Subject to data availability)
        • 1.2.14.4 R&D Investment (Subject to data availability)
        • 1.2.14.5 Product Types Specification
        • 1.2.14.6 Business Strategy
        • 1.2.14.7 Recent Developments
        • 1.2.14.8 Management Change
        • 1.2.14.9 S.W.O.T Analysis
      • 1.2.15 Inc.
        • 1.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.15.2 Business Overview
        • 1.2.15.3 Financials (Subject to data availability)
        • 1.2.15.4 R&D Investment (Subject to data availability)
        • 1.2.15.5 Product Types Specification
        • 1.2.15.6 Business Strategy
        • 1.2.15.7 Recent Developments
        • 1.2.15.8 Management Change
        • 1.2.15.9 S.W.O.T Analysis
      • 1.2.16 Kimberly-Clark Corporation
        • 1.2.16.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.16.2 Business Overview
        • 1.2.16.3 Financials (Subject to data availability)
        • 1.2.16.4 R&D Investment (Subject to data availability)
        • 1.2.16.5 Product Types Specification
        • 1.2.16.6 Business Strategy
        • 1.2.16.7 Recent Developments
        • 1.2.16.8 Management Change
        • 1.2.16.9 S.W.O.T Analysis
      • 1.2.17 Abbott Laboratories
        • 1.2.17.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.17.2 Business Overview
        • 1.2.17.3 Financials (Subject to data availability)
        • 1.2.17.4 R&D Investment (Subject to data availability)
        • 1.2.17.5 Product Types Specification
        • 1.2.17.6 Business Strategy
        • 1.2.17.7 Recent Developments
        • 1.2.17.8 Management Change
        • 1.2.17.9 S.W.O.T Analysis
      • 1.2.18 Salix Pharmaceuticals
        • 1.2.18.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.18.2 Business Overview
        • 1.2.18.3 Financials (Subject to data availability)
        • 1.2.18.4 R&D Investment (Subject to data availability)
        • 1.2.18.5 Product Types Specification
        • 1.2.18.6 Business Strategy
        • 1.2.18.7 Recent Developments
        • 1.2.18.8 Management Change
        • 1.2.18.9 S.W.O.T Analysis
      • 1.2.19 Inc
        • 1.2.19.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.19.2 Business Overview
        • 1.2.19.3 Financials (Subject to data availability)
        • 1.2.19.4 R&D Investment (Subject to data availability)
        • 1.2.19.5 Product Types Specification
        • 1.2.19.6 Business Strategy
        • 1.2.19.7 Recent Developments
        • 1.2.19.8 Management Change
        • 1.2.19.9 S.W.O.T Analysis
      • 1.2.20 Boston Scientific Corporation
        • 1.2.20.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.20.2 Business Overview
        • 1.2.20.3 Financials (Subject to data availability)
        • 1.2.20.4 R&D Investment (Subject to data availability)
        • 1.2.20.5 Product Types Specification
        • 1.2.20.6 Business Strategy
        • 1.2.20.7 Recent Developments
        • 1.2.20.8 Management Change
        • 1.2.20.9 S.W.O.T Analysis
      • 1.2.21 C. R. Bard
        • 1.2.21.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.21.2 Business Overview
        • 1.2.21.3 Financials (Subject to data availability)
        • 1.2.21.4 R&D Investment (Subject to data availability)
        • 1.2.21.5 Product Types Specification
        • 1.2.21.6 Business Strategy
        • 1.2.21.7 Recent Developments
        • 1.2.21.8 Management Change
        • 1.2.21.9 S.W.O.T Analysis
      • 1.2.22 Inc
        • 1.2.22.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.22.2 Business Overview
        • 1.2.22.3 Financials (Subject to data availability)
        • 1.2.22.4 R&D Investment (Subject to data availability)
        • 1.2.22.5 Product Types Specification
        • 1.2.22.6 Business Strategy
        • 1.2.22.7 Recent Developments
        • 1.2.22.8 Management Change
        • 1.2.22.9 S.W.O.T Analysis
      • 1.2.23 Janssen Global Services LLC
        • 1.2.23.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.23.2 Business Overview
        • 1.2.23.3 Financials (Subject to data availability)
        • 1.2.23.4 R&D Investment (Subject to data availability)
        • 1.2.23.5 Product Types Specification
        • 1.2.23.6 Business Strategy
        • 1.2.23.7 Recent Developments
        • 1.2.23.8 Management Change
        • 1.2.23.9 S.W.O.T Analysis
      • 1.2.24 Cardinal Health
        • 1.2.24.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.24.2 Business Overview
        • 1.2.24.3 Financials (Subject to data availability)
        • 1.2.24.4 R&D Investment (Subject to data availability)
        • 1.2.24.5 Product Types Specification
        • 1.2.24.6 Business Strategy
        • 1.2.24.7 Recent Developments
        • 1.2.24.8 Management Change
        • 1.2.24.9 S.W.O.T Analysis
      • 1.2.25 Inc.
        • 1.2.25.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.25.2 Business Overview
        • 1.2.25.3 Financials (Subject to data availability)
        • 1.2.25.4 R&D Investment (Subject to data availability)
        • 1.2.25.5 Product Types Specification
        • 1.2.25.6 Business Strategy
        • 1.2.25.7 Recent Developments
        • 1.2.25.8 Management Change
        • 1.2.25.9 S.W.O.T Analysis
      • 1.2.26 Alfa Wassermann SPA
        • 1.2.26.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.26.2 Business Overview
        • 1.2.26.3 Financials (Subject to data availability)
        • 1.2.26.4 R&D Investment (Subject to data availability)
        • 1.2.26.5 Product Types Specification
        • 1.2.26.6 Business Strategy
        • 1.2.26.7 Recent Developments
        • 1.2.26.8 Management Change
        • 1.2.26.9 S.W.O.T Analysis
      • 1.2.27 Evoke Pharma
        • 1.2.27.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.27.2 Business Overview
        • 1.2.27.3 Financials (Subject to data availability)
        • 1.2.27.4 R&D Investment (Subject to data availability)
        • 1.2.27.5 Product Types Specification
        • 1.2.27.6 Business Strategy
        • 1.2.27.7 Recent Developments
        • 1.2.27.8 Management Change
        • 1.2.27.9 S.W.O.T Analysis
      • 1.2.28 Rhythm Pharmaceuticals
        • 1.2.28.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.28.2 Business Overview
        • 1.2.28.3 Financials (Subject to data availability)
        • 1.2.28.4 R&D Investment (Subject to data availability)
        • 1.2.28.5 Product Types Specification
        • 1.2.28.6 Business Strategy
        • 1.2.28.7 Recent Developments
        • 1.2.28.8 Management Change
        • 1.2.28.9 S.W.O.T Analysis
      • 1.2.29 Inc
        • 1.2.29.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.29.2 Business Overview
        • 1.2.29.3 Financials (Subject to data availability)
        • 1.2.29.4 R&D Investment (Subject to data availability)
        • 1.2.29.5 Product Types Specification
        • 1.2.29.6 Business Strategy
        • 1.2.29.7 Recent Developments
        • 1.2.29.8 Management Change
        • 1.2.29.9 S.W.O.T Analysis

  • Chapter 2. Global Gastroparesis Drugs Market Analysis

    • 2.1 Global Gastroparesis Drugs Market Analysis
    • 2.2 Global Gastroparesis Drugs Market Analysis by Region
    • 2.3 Global Gastroparesis Drugs Market Analysis by Drug Type
    • 2.4 Global Gastroparesis Drugs Market Analysis by End-User
    • 2.5 Global Gastroparesis Drugs Market Analysis by Disease Type
    • 2.6 Global Gastroparesis Drugs Market Analysis by Key Players

  • Chapter 3. North America Gastroparesis Drugs Market Analysis

    • 3.1 North America Gastroparesis Drugs Market Analysis
    • 3.2 North America Gastroparesis Drugs Market Analysis by Country
    • 3.3 North America Gastroparesis Drugs Market Analysis by Drug Type
    • 3.4 North America Gastroparesis Drugs Market Analysis by End-User
    • 3.5 North America Gastroparesis Drugs Market Analysis by Disease Type
    • 3.6 North America Gastroparesis Drugs Market Analysis by Key Players

  • Chapter 4. Europe Gastroparesis Drugs Market Analysis

    • 4.1 Europe Gastroparesis Drugs Market Analysis
    • 4.2 Europe Gastroparesis Drugs Market Analysis by Country
    • 4.3 Europe Gastroparesis Drugs Market Analysis by Drug Type
    • 4.4 Europe Gastroparesis Drugs Market Analysis by End-User
    • 4.5 Europe Gastroparesis Drugs Market Analysis by Disease Type
    • 4.6 Europe Gastroparesis Drugs Market Analysis by Key Players

  • Chapter 5. Asia Pacific Gastroparesis Drugs Market Analysis

    • 5.1 Asia Pacific Gastroparesis Drugs Market Analysis
    • 5.2 Asia Pacific Gastroparesis Drugs Market Analysis by Country
    • 5.3 Asia Pacific Gastroparesis Drugs Market Analysis by Drug Type
    • 5.4 Asia Pacific Gastroparesis Drugs Market Analysis by End-User
    • 5.5 Asia Pacific Gastroparesis Drugs Market Analysis by Disease Type
    • 5.6 Asia Pacific Gastroparesis Drugs Market Analysis by Key Players

  • Chapter 6. South America Gastroparesis Drugs Market Analysis

    • 6.1 South America Gastroparesis Drugs Market Analysis
    • 6.2 South America Gastroparesis Drugs Market Analysis by Country
    • 6.3 South America Gastroparesis Drugs Market Analysis by Drug Type
    • 6.4 South America Gastroparesis Drugs Market Analysis by End-User
    • 6.5 South America Gastroparesis Drugs Market Analysis by Disease Type
    • 6.6 South America Gastroparesis Drugs Market Analysis by Key Players

  • Chapter 7. Middle East Gastroparesis Drugs Market Analysis

    • 7.1 Middle East Gastroparesis Drugs Market Analysis
    • 7.2 Middle East Gastroparesis Drugs Market Analysis by Country
    • 7.3 Middle East Gastroparesis Drugs Market Analysis by Drug Type
    • 7.4 Middle East Gastroparesis Drugs Market Analysis by End-User
    • 7.5 Middle East Gastroparesis Drugs Market Analysis by Disease Type
    • 7.6 Middle East Gastroparesis Drugs Market Analysis by Key Players

  • Chapter 8. Africa Gastroparesis Drugs Market Analysis

    • 8.1 Africa Gastroparesis Drugs Market Analysis
    • 8.2 Africa Gastroparesis Drugs Market Analysis by Country
    • 8.3 Africa Gastroparesis Drugs Market Analysis by Drug Type
    • 8.4 Africa Gastroparesis Drugs Market Analysis by End-User
    • 8.5 Africa Gastroparesis Drugs Market Analysis by Disease Type
    • 8.6 Africa Gastroparesis Drugs Market Analysis by Key Players

  • Chapter 9. Drug Type Analysis

    • 9.1 Antiemetic Agents
      • 9.1.1 Global Antiemetic Agents Market
      • 9.1.2 Global Antiemetic Agents Market by Region
    • 9.2 Prokinetic Agents
      • 9.2.1 Global Prokinetic Agents Market
      • 9.2.2 Global Prokinetic Agents Market by Region
    • 9.3 Botulinum Toxin Injections
      • 9.3.1 Global Botulinum Toxin Injections Market
      • 9.3.2 Global Botulinum Toxin Injections Market by Region

  • Chapter 10. End-User Analysis

    • 10.1 Hospitals
      • 10.1.1 Global Hospitals Market
      • 10.1.2 Global Hospitals Market by Region
    • 10.2 Clinics
      • 10.2.1 Global Clinics Market
      • 10.2.2 Global Clinics Market by Region
    • 10.3 Pharmacies
      • 10.3.1 Global Pharmacies Market
      • 10.3.2 Global Pharmacies Market by Region

  • Chapter 11. Disease Type Analysis

    • 11.1 Diabetic Gastroparesis
      • 11.1.1 Global Diabetic Gastroparesis Market
      • 11.1.2 Global Diabetic Gastroparesis Market by Region
    • 11.2 Post-Surgical Gastroparesis
      • 11.2.1 Global Post-Surgical Gastroparesis Market
      • 11.2.2 Global Post-Surgical Gastroparesis Market by Region
    • 11.3 Idiopathic Gastroparesis
      • 11.3.1 Global Idiopathic Gastroparesis Market
      • 11.3.2 Global Idiopathic Gastroparesis Market by Region
    • 11.4 Other Disease Types
      • 11.4.1 Global Other Disease Types Market
      • 11.4.2 Global Other Disease Types Market by Region

  • Chapter 12. Qualitative Analysis (Subject to Data Availability)

    • 12.1 Market Drivers
    • 12.2 Market Restraints
    • 12.3 Market Trends
    • 12.4 Market Opportunity
    • 12.5 Technological Road Map (Subject to Data Availability)
    • 12.6 Product Life Cycle (Subject to Data Availability)
    • 12.7 Customer and Buyer Behavior Analysis
      • 12.7.1 Digital Engagement, Customer Experience & Relationship Analysis
      • 12.7.2 Customer Buying Behavior & Purchase Decision Analysis
      • 12.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
      • 12.7.4 Pricing, Affordability & Value Perception Analysis
      • 12.7.5 Customer Segmentation & Demand Pattern Analysis
    • 12.8 PESTEL Analysis
      • 12.8.1 Political Factors
      • 12.8.2 Economic Factors
      • 12.8.3 Social Factors
      • 12.8.4 Technological Factors
      • 12.8.5 Legal Factors
      • 12.8.6 Environmental Factors
    • 12.9 Industrial Chain Analysis (Subject to Data Availability)
      • 12.9.1 Industry Chain Analysis
      • 12.9.2 Manufacturing Cost Analysis
      • 12.9.3 Supply Side Analysis
        • 12.9.3.1 Raw Material Analysis
        • 12.9.3.2 Raw Material Procurement Analysis
        • 12.9.3.3 Raw Material Price Trend Analysis
    • 12.10 Porter’s Five Forces Analysis
      • 12.10.1 Bargaining Power of Suppliers
      • 12.10.2 Bargaining Power of Buyers
      • 12.10.3 Threat of New Entrants
      • 12.10.4 Threat of Substitutes
      • 12.10.5 Degree of Competition
    • 12.11 Patent Analysis (Subject to Data Availability)
    • 12.12 ESG Analysis
    • 12.13 Geopolitical Outlook
      • 12.13.1 Global Power Realignment & Strategic Alliances
      • 12.13.2 Geopolitical Risk Landscape & Conflict Hotspots
      • 12.13.3 International Trade Relations & Market Access Environment
      • 12.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
      • 12.13.5 Supply Chain Resilience, Localization & Resource Nationalism
      • 12.13.6 Technology Sovereignty & Digital Geopolitics
      • 12.13.7 Strategic Implications for Investment, Growth & Market Entry
    • 12.14 AI & Market Transformation
      • 12.14.1 Competitive Landscape Disruption & Strategic Shifts
      • 12.14.2 AI-Driven Transformation of Industry Value Chain
      • 12.14.3 Evolution of Business Models & Revenue Streams
      • 12.14.4 AI-Driven Product, Service & Innovation Transformation
      • 12.14.5 Customer Behavior, AI Adoption & Future Market Evolution

  • Chapter 13. TOP 10 Country Analysis

    • 13.1 Country 1
    • 13.2 Country 2
    • 13.3 Country 3
    • 13.4 Country 4
    • 13.5 Country 5
    • 13.6 Country 6
    • 13.7 Country 7
    • 13.8 Country 8
    • 13.9 Country 9
    • 13.10 Country 10

  • Chapter 14. Research Findings

    • 14.1 Key Takeaways
    • 14.2 Analyst Point of View
    • 14.3 Assumptions and Acronyms

  • Chapter 15. Research Methodology and Sources

    • 15.1 Primary Data Collection
      • 15.1.1 Steps for Primary Data Collection
        • 15.1.1.1 Identification of KOL
      • 15.1.2 Backward Integration
      • 15.1.3 Forward Integration
      • 15.1.4 How Primary Research Help Us
      • 15.1.5 Modes of Primary Research
    • 15.2 Secondary Research
      • 15.2.1 How Secondary Research Help Us
      • 15.2.2 Sources of Secondary Research
    • 15.3 Data Validation
      • 15.3.1 Data Triangulation
    • 15.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Gastroparesis Drugs Market Analysis Market analysis.

01

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

02

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

03

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

04

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

05

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics
Data Points Validated 10,400+
Expert Interviews 54
Countries Covered 39+
Company Profiles 29+
Forecast Accuracy (Historical) 94.2%
Analytical Coverage
Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Latest News about Gastroparesis Drugs Market

In December 2023 – Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced that the FDA has accepted the filing of Vanda’s New Drug Application (NDA) for precipitant. Tradipitant is intended to be used for treating symptoms of gastroparesis.
Source:(https://www.nasdaq.com/press-release/vanda-pharmaceuticals-announces-that-u.s.-food-and-drug-administration-accepts-new)

In February 2023, Renexxion Ireland announced the start of a Phase IIb trial of gastroparesis therapy. This trial has been mainly designed to assess the safety, tolerability, and efficacy of naronapride among gastroparesis patients. It will further help in the development of new drugs for gastroparesis.
Source:(https://www.clinicaltrialsarena.com/news/renexxion-ireland-gastroparesis-therapy/)

In December 2022, Evoke Pharma, Inc. announced that the United States Patent and Trademark Office (USPTO) issued a United States Patent No. 11,517,545 under the title 'Treatment of Moderate and Severe Gastroparesis'' which covers the usage of GIMOTI.
Source:(https://www.biospace.com/article/releases/uspto-grants-new-patent-to-evoke-pharma-covering-the-usage-of-gimoti-to-treat-moderate-to-severe-gastroparesis/)


 

Sources from the Pharma and Healthcare Industry

How We Serve You

The Three Pillars of End-to-End Market Research Services

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Gastroparesis Drugs Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the gastroparesis drugs market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included
  • Buyer intent & sentiment analysis
  • Purchase cycle mapping
  • Price sensitivity research
  • Channel preference profiling
  • Competitive perception study
Most Requested
Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included
  • Ready syndicate report
  • Custom data scope & segmentation
  • Excel quantitative models
  • Board-ready PPT with key findings
  • Secure cloud portal access
Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included
  • Dedicated analyst assigned to you
  • Live walkthrough of findings
  • Strategic Q&A sessions
  • Go-to-market recommendations
  • NDA-protected engagement

Customize This Report

Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.